Jasper Therapeutics (JSPR) News Today $4.14 -0.16 (-3.72%) Closing price 04:00 PM EasternExtended Trading$4.17 +0.03 (+0.70%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Decreases By 19.7%Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 1,670,000 shares, a decline of 19.7% from the February 28th total of 2,080,000 shares. Based on an average daily volume of 526,700 shares, the days-to-cover ratio is currently 3.2 days. Currently, 14.1% of the company's stock are short sold.April 1 at 6:11 AM | marketbeat.comJasper Therapeutics inks new sales agreement, ends previous dealMarch 21, 2025 | uk.investing.comJasper Therapeutics files $300M mixed securities shelfMarch 19, 2025 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest UpdateJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant decrease in short interest in February. As of February 28th, there was short interest totalling 2,080,000 shares, a decrease of 16.8% from the February 13th total of 2,500,000 shares. Currently, 17.5% of the company's shares are short sold. Based on an average trading volume of 522,500 shares, the days-to-cover ratio is currently 4.0 days.March 19, 2025 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Recommendation of "Buy" by AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has received a consensus rating of "Buy" from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating. The average twelve-month price target among brokeraMarch 17, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday.March 12, 2025 | marketbeat.comFY2025 EPS Estimates for JSPR Raised by Cantor FitzgeraldJasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates thatMarch 7, 2025 | marketbeat.comEquities Analysts Set Expectations for JSPR Q1 EarningsJasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Investment analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research report issued on Thursday, February 27th. William Blair analyst M. Phipps anticipates that the compaMarch 3, 2025 | marketbeat.comJasper Therapeutics presents updated data from Phase 1b/2a BEACON studyMarch 2, 2025 | msn.comJasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingMarch 1, 2025 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Announces Earnings Results, Misses Estimates By $0.42 EPSJasper Therapeutics (NASDAQ:JSPR - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.42).February 28, 2025 | marketbeat.comJasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual MeetingFebruary 28, 2025 | globenewswire.comJasper Therapeutics Reports Promising Clinical ProgressFebruary 28, 2025 | tipranks.comJasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23)February 27, 2025 | markets.businessinsider.comJasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | globenewswire.comJasper Therapeutics to Present at Upcoming March Investor ConferencesFebruary 25, 2025 | globenewswire.comJasper Therapeutics (JSPR) to Release Quarterly Earnings on MondayJasper Therapeutics (NASDAQ:JSPR) will be releasing earnings before the market opens on Monday, March 3.February 24, 2025 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from BrokeragesJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Eleven analysts have rated the stock with a buy rating. The average 12 month price target amoFebruary 20, 2025 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 15.5% in JanuaryJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the recipient of a large decline in short interest in January. As of January 31st, there was short interest totalling 2,720,000 shares, a decline of 15.5% from the January 15th total of 3,220,000 shares. Approximately 24.2% of the shares of the company are sold short. Based on an average trading volume of 477,000 shares, the short-interest ratio is currently 5.7 days.February 17, 2025 | marketbeat.comUBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy RecommendationFebruary 14, 2025 | msn.comJasper Therapeutics initiated with a Buy at UBSFebruary 13, 2025 | markets.businessinsider.comUBS Group Begins Coverage on Jasper Therapeutics (NASDAQ:JSPR)UBS Group initiated coverage on Jasper Therapeutics in a research note on Thursday. They set a "buy" rating and a $38.00 price objective on the stock.February 13, 2025 | marketbeat.comJasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingFebruary 10, 2025 | globenewswire.comJasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comAnalysts Offer Predictions for JSPR FY2025 EarningsJasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that theJanuary 22, 2025 | marketbeat.comShort Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1%Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,320,000 shares, a growth of 12.1% from the December 15th total of 2,070,000 shares. Approximately 20.6% of the shares of the company are sold short. Based on an average daily trading volume, of 412,100 shares, the short-interest ratio is presently 5.6 days.January 18, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for JSPR Q1 Earnings?Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar forecasts that the companyJanuary 13, 2025 | marketbeat.comJasper Therapeutics price target lowered to $48 from $68 at RBC CapitalJanuary 10, 2025 | markets.businessinsider.comHC Wainwright Has Lowered Expectations for Jasper Therapeutics (NASDAQ:JSPR) Stock PriceHC Wainwright dropped their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday.January 10, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for JSPR FY2029 Earnings?Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company wilJanuary 10, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Given New $48.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada decreased their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday.January 9, 2025 | marketbeat.comStrong Therapeutic Potential and Financial Outlook for Jasper Therapeutics’ BriquilimabJanuary 9, 2025 | markets.businessinsider.comJasper Therapeutics price target lowered to $64 from $90 at BTIGJanuary 9, 2025 | markets.businessinsider.comJasper Therapeutics stock tumbles after study dataJanuary 8, 2025 | investing.comJasper Therapeutics reports data from BEACON study of briquilimabJanuary 8, 2025 | markets.businessinsider.comJasper data alleviates competitive concerns for Celldex, says CitiJanuary 8, 2025 | markets.businessinsider.comJasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous UrticariaJanuary 8, 2025 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Receives "Market Outperform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday.January 6, 2025 | marketbeat.comJasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025January 6, 2025 | globenewswire.comJasper Therapeutics Positioned for Success in Urticaria Market with Upcoming Briquilimab DataJanuary 6, 2025 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has earned an average rating of "Buy" from the ten brokerages that are currently covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages thatJanuary 1, 2025 | marketbeat.comJasper Therapeutics' (JSPR) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research note on Monday.December 23, 2024 | marketbeat.comFranklin Resources Inc. Sells 118,900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)Franklin Resources Inc. cut its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 17.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 579,636 shares of theDecember 22, 2024 | marketbeat.comWellington Management Group LLP Buys New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Wellington Management Group LLP purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,759 shares of the company's stock, valuedDecember 21, 2024 | marketbeat.comFmr LLC Acquires Shares of 38,361 Jasper Therapeutics, Inc. (NASDAQ:JSPR)Fmr LLC bought a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,361 shares of the company's stock, valued at approximately $722,000. Fmr LLC ownDecember 18, 2024 | marketbeat.comInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of StockDecember 13, 2024 | insidertrades.comVerition Fund Management LLC Makes New $477,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Verition Fund Management LLC acquired a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,353 shares of the company's stock,December 12, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Rating of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among brDecember 7, 2024 | marketbeat.comJasper Therapeutics initiated with an Outperform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comBMO Capital Initiates Coverage of Jasper Therapeutics (JSPR) with Outperform RecommendationDecember 6, 2024 | msn.com Remove Ads Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address JSPR Media Mentions By Week JSPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼1.600.78▲Average Medical News Sentiment JSPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼32▲JSPR Articles Average Week Remove Ads Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Septerna News Olema Pharmaceuticals News Immutep News Atea Pharmaceuticals News ProKidney News Bright Minds Biosciences News Gossamer Bio News Acelyrin News MBX Biosciences News Aurora Cannabis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
